Immunological markers of optimal response to natalizumab in multiple sclerosis

Archives of Neurology
Luisa M VillarJose C Alvarez-Cermeño

Abstract

To explore cell subsets and molecules that changed specifically in patients with multiple sclerosis (MS) who had an optimal response to natalizumab. Natalizumab is a monoclonal antibody that inhibits the migration of activated immune cells to the central nervous system. It shows high efficacy in modifying the natural history of MS and induces freedom of disease activity in about 40% of treated patients with MS. Prospective study of intrathecal immunoglobulin synthesis and cerebrospinal fluid lymphocyte subsets in patients with MS before and 1 year after beginning treatment with natalizumab. We monitored clinical and magnetic resonance imaging activity during a median time of 2 years. Two tertiary hospitals from the Spanish National Health Service. A total of 23 patients with MS. The differences between patients free of disease activity and patients with active disease during treatment. Of the 23 patients, 10 (43.5%) remained free of disease activity during follow-up. The remaining 13 patients (56.5%) had relapses or new lesions despite natalizumab therapy. We did not find differences in demographic variables or clinical data between both groups prior to natalizumab therapy. All patients showed a decrease in cerebrospinal fluid ...Continue Reading

Citations

Feb 8, 2013·Biomarkers in Medicine·Vera PravicaMarija Mostarica-Stojkovic
Aug 8, 2014·Science Translational Medicine·Arumugam PalanichamyH-Christian von Büdingen
Aug 8, 2014·Science Translational Medicine·Joel N H SternKevin C O'Connor
Jan 5, 2016·Nihon Rinshō Men'eki Gakkai kaishi = Japanese journal of clinical immunology·Masakazu NakamuraTakashi Yamamura
Jan 1, 2014·Annals of Neurology·Jaishree BankotiH-Christian von Büdingen
Jul 31, 2013·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·O OutteryckUNKNOWN CFSEP
Apr 26, 2016·Neurology. Neuroimmunology and Neuroinflammation·Gregory F Wu, Erin E Longbrake
Dec 3, 2016·Expert Review of Molecular Diagnostics·Matteo GastaldiDiego Franciotta
Jan 21, 2016·Therapeutic Advances in Neurological Disorders·Finn SellebjergDaniel Mikol
Feb 27, 2013·Multiple Sclerosis : Clinical and Laboratory Research·Rebecca C SelterBernhard Hemmer
Jun 21, 2014·Multiple Sclerosis : Clinical and Laboratory Research·R MancusoM Clerici
Jul 24, 2013·Multiple Sclerosis : Clinical and Laboratory Research·Giannina ArruGiuseppe Mameli
Dec 5, 2017·JCI Insight·Erica L EggersH-Christian von Büdingen
Oct 10, 2012·Nature Reviews. Neurology·Markus KrumbholzEdgar Meinl
Mar 27, 2013·Nature Reviews. Neurology·Martin StangelHayrettin Tumani
Jan 6, 2017·Neurology. Neuroimmunology and Neuroinflammation·Alexander SchwarzJürgen Haas
Apr 24, 2013·Current Treatment Options in Neurology·Tiffany J Braley, Benjamin M Segal
Oct 20, 2020·Frontiers in Immunology·Kathy KhoyBrigitte Le Mauff
Feb 25, 2021·Cellular and Molecular Neurobiology·Ursula MuñozMari Cruz Sadaba
May 14, 2021·Multiple Sclerosis and Related Disorders·Alexander Cuculiza HenriksenJeppe Romme Christensen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

CSF & Lymphatic System

This feed focuses on Cerebral Spinal Fluid (CSF) and the lymphatic system. Discover the latest papers using imaging techniques to track CSF outflow into the lymphatic system in animal models.

B cell Differentiation

Depending on the signal received through the B cell receptor and other receptors, B cells differentiate into follicular or marginal zone B cells. Here is the latest research pertaining to this differentiation process.